The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradation

Molecular Cancer Research

Volumn 12, Issue 11, 2014, Pages 1621-1634

  Aronchik, Ida ^a   Kundu, Aishwarya ^a   Quirit, Jeanne G ^a   Firestone, Gary L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE NEDD4; ESCRT PROTEIN; INDOLE DERIVATIVE; INDOLE-3-CARBINOL; NEDD4 UBIQUITIN PROTEIN LIGASES; PROTEASOME; PROTEIN BINDING; PTEN PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL MELANOMA; GENE DISRUPTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTHERMAL TITRATION CALORIMETRY; MELANOCYTE; MELANOMA CELL; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; UBIQUITINATION; WILD TYPE; ANIMAL; CALORIMETRY; CELL CYCLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; MELANOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTEIN SECONDARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CALORIMETRY; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; DOWN-REGULATION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HUMANS; INDOLES; MELANOMA; MICE, NUDE; MODELS, MOLECULAR; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEOLYSIS; PTEN PHOSPHOHYDROLASE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910615722     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0018     Document Type: Article

References (53)

1. Chakraborty R, Wieland CN, Comfere NI. Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med 2013;6: 49-56.
2. Banarchi B, Jabbari CA, Vedadi A, Navab R. Molecular biology of normal melanocytes and melanoma cells. J Clin Pathol 2013;66: 644-8.
3. Kawaskaki BT, Hurt EM, Mistree T, Farrar WL. Targeting cancer stem cells with phytochemicals. Mol Interv 2008;8:174-84.
4. Higdon B, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007;55:224-36.
5. Sarkar FH, Li Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 2009;35: 597-607.
6. Ahmad A, Sakr WA, Rahman KM. Novel targets for detection of cancer and their modulation by chemopreventative natural compounds. Front Biosci 2012;4:410-25.
7. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005;4:1201-15.
8. Ahmad A, Sakr WA, Rahman KM. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets 2010;11:652-66.
9. Firestone GL, Sundar SN. Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Mol Endocrinol 2009;23: 1940-7.
10. Firestone GL, Bjeldanes LF. Indole-3-carbinol (I3C) and 3-30-diindolylmethane (DIM) anti-proliferative signaling pathways control cell cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 2003;133: 2448S-55S.
11. Garcia HH, Brar GA, Nguyen DHH, Bjeldanes LF, Firestone GL. Indole-3-carbinol (I3C) inhibits cyclin dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms and subcellular localization of the CDK2 protein complex. J Biol Chem 2005;280:8756-64.
12. Marconett CN, Sundar SN, Poindexter KM, Stueve TR, Bjeldanes LF, Firestone GL. Indole-3-carbinol triggers AhR-dependent ERalpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop. Mol Biol Cell 2010;21:1166-77.
13. Marconett CN, Sundar SN, Tseng M, Tin AS, Tran K, Mahuron K, et al. Indole-3-carbinol down-regulation of telomerase gene expression requires the inhibition of estrogen receptor-Alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates theG1 cell cycle arrest of human breast cancer cells. Carcinogenesis 2011;32:1315-23.
14. Brew CT, Aronchik I, Kosco K, McCammon J, Bjeldanes LF, Firestone GL. Indole-3-carbinol inhibits MDA-MB-231 breast cancer cell motility and induces stress fibers and focal adhesion formation by activation of Rho kinase activity. Int J Cancer 2009;124: 2294-302.
15. Jeong YM, Li H, Kim SY, Yun HY, Baek KJ, Kwon NS, et al. Indole-3-carbinol inhibits prostate cancer cell migration via degradation of betacatenin. Oncol Res 2011;19:237-43.
16. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling pertubations by natural products. Cell Signal 2009;21:1541-7.
17. Xu Y, Zhang J, Dong WG. Indole-3-carbinol (I3C)-induced apoptosis in nasopharyngeal cancer cells through Fas/FasL and MAPK pathway. Med Oncol 2011;28:1343-8.
18. Bai LY, Weng JR, Chiu CF, Wu CY, Yeh SP, Sargeant AM, et al. OSU-19, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis. Biochem Pharmacol 2013;86:1430-40.
19. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GF. The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci U S A 2008;105:19750-5.
20. Aronchik I, Bjeldanes LF, Firestone GL. Direct inhibition of elastase activity by indole-3-carbinol triggers a CD40-TRAF regulatory cascade that disrupts NFkB transcriptional activity in human breast cancer cells. Cancer Res 2010;70:4961-71.
21. Aronchik I, Chen T, Durkin KA, Horwitz MS, Preobrazhenskaya MN, Bjeldanes LF, et al. Target protein interactions of indole-3-carbinol and the highly potent derivative 1-benzyl-I3C with the C-terminal domain of human elastase uncouples cell cycle arrest from apoptotic signaling. Mol Carcinog 2012;51:881-94.
22. Kim SY, Kima DS, Jeong YM, Moon SI, Kwon SB, Park KC. Indole-3-carbinol and ultraviolet B induce apoptosis of human melanoma cells via down regulation of MITF. Pharmazie 2011;66:982-7.
23. Kim DS, Jeong YM, Moon SI, Kim SY, Kwon SB, Park ES, et al. Indole-3-carbinol enhances ultraviolet B-induced apoptosis by sensitizing human melanoma cells. Cell Mol Life Sci 2006;63:2661-8.
24. Dahler AL, Rickwood D, Guminski A, Teakle N, Saunder NA. Indole-3-carbinol induced growth inhibition can be converted to a cytotoxic response in the presence of TPA + Ca2+ in squamous cell carcinoma cell lines. FEBS Lett 2007;581:3839-47.
25. Aguissa-Toure AH, Li G. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci 2012;69:1475-91.
26. Conde-Perez A, Larue L. PTEN and melanogenesis. Future Oncol 2012;8:1109-20.
27. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 2010;130:620-2.
28. Stahl JM, Cheung M, Sharma A, Trivedi NR, ShanmugamS, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2881-90.
29. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000;157:1123-8.
30. Herbst RA, Weiss J, Ehnis A, Cavenee WK, Arden KC. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 1994;54:3111-4.
31. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22:3113-22.
32. Ming M, He YY. PTEN: new insights into its regulation and function in skin cancer. J Invest Dermatol 2009;129:2109-12.
33. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 2005;24: 273-85.
34. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007; 128:129-39.
35. Cen H, Mao F, Aronchik I, Fuentes RJ, Firestone GL. DEVD-Nuc-View488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells. FASEB J 2008;22:2243-52.
36. Ritchie DW, Ghoorah AW, Mavridis L, Venkatraman V. Fast protein structure alignment using gaussian overlap scoring of backbone peptide fragment similarity. Bioinformatics 2012;28:3274-81.
37. DeLano WL. Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 2002;12:14-20
38. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8:127-34.
39. Staub RE, Feng C, Onisko B, Bailey GS, Firestone GL, Bjeldanes LF. Fate of indole-3-carbinol in cultured human breast tumor cells. Chem Res Toxicol 2002;15:101-9.
40. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-82.
41. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002;277:21843-50.
42. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
43. Mund T, Pelham HR. Control of the activity of WW-HECT domain E3 ubiquitin ligases by NDFIP proteins. EMBO Rep 2009;10:501-7.
44. Mund T, Pelham HR. Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2. Proc Natl Acad Sci U S A 2010;107:11429-34.
45. Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, et al. P34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ 2014;21:146-60.
46. Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, et al. The ubiquitin ligase NEDD4-1 is dispensible for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A 2008;105:8585-90.
47. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251-63.
48. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010;467:596-9.
49. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
50. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
51. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011;71: 2750-60.
52. Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, et al. A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 2005;14: 1953-60.
53. Reed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, et al. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,30-diindolylmethane. Cancer Epidemiol Biomarkers Prev 2006;15:2477-81.